^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Descartes-08
i
Other names: Descartes-08, anti-BCMA chimeric antigen receptor T cell therapy, Descartes08, Descartes 08
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Cartesian Therapeutics
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
20d
Descartes-08 in Autoantibody Myositis (clinicaltrials.gov)
P2, N=60, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: Nov 2026 --> Nov 2027
Enrollment open • Trial completion date • Trial primary completion date
|
Descartes-08
1m
Descartes-08 in Autoantibody Myositis (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Cartesian Therapeutics | Initiation date: Mar 2026 --> Jun 2026
Trial initiation date
|
Descartes-08
2ms
SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Cartesian Therapeutics | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
Descartes-08
2ms
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
P1/2, N=50, Recruiting, Cartesian Therapeutics | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
Trial completion date • Trial primary completion date
|
Descartes-08
3ms
Descartes-08 in Autoantibody Myositis (clinicaltrials.gov)
P2, N=60, Not yet recruiting, Cartesian Therapeutics
New P2 trial
|
Descartes-08
4ms
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
P1/2, N=50, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
Descartes-08
6ms
SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
P2, N=6, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | N=30 --> 6
Enrollment closed • Enrollment change
|
Descartes-08
10ms
Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis (clinicaltrials.gov)
P1/2, N=50, Not yet recruiting, Cartesian Therapeutics
New P1/2 trial
|
Descartes-08
12ms
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Cartesian Therapeutics | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2025 --> Jul 2025
Enrollment closed • Trial primary completion date
|
Descartes-08
1year
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
Descartes-08
1year
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Not yet recruiting, Cartesian Therapeutics | Trial completion date: Apr 2026 --> Sep 2027 | Trial primary completion date: Apr 2026 --> Nov 2026
Trial completion date • Trial primary completion date
|
Descartes-08
over1year
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis (clinicaltrials.gov)
P3, N=100, Recruiting, Cartesian Therapeutics
New P3 trial
|
Descartes-08
Share via
